Shareholding disclosure

Fabrice Evangelista

Declared position

14.83%

Threshold

Crossed upwards

Timeline

Published

19.11.2020

Transaction

13.11.2020

Transfer date

16.11.2020

Voting rights breakdown

Voting rights acquired14.83%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAKBI000A7

Beneficial owner

Fabrice Evangelista

Declared address

Fabrice Evangelista, Neuilly sur Seine

Expiration of securities lending

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Fabrice Evangelista

Santhera Pharmaceuticals Holding AG19.11.2020TAKBI000A7

Disclosure summary

Fabrice Evangelista disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 19.11.2020, at 14.83% of voting rights. Notice category: Single shareholder.

Disclosed position

14.83%

Voting rights acquired

Voting rights acquired14.83%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Fabrice Evangelista disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 19.11.2020.

Publication date19.11.2020

Transaction date13.11.2020

Transfer date16.11.2020

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerFabrice Evangelista

Declared addressFabrice Evangelista, Neuilly sur Seine

CategorySingle shareholder

Voting rights acquired14.83%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAKBI000A7

Conditions

Expiration of securities lending

Source: SIX Exchange Regulation · Publication date: 19.11.2020

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open